Are you ready to drop Jakafi from your options.
UK’s National Institute for Health Excellence (NICE) influences about 25% of the world’s prescription of novel drugs.
It is currently reviewing the cost-effectiveness of ruxolitinib (JAKAVI/JAKAFI) for myelofibrosis and soliciting input from the affected patient population.
We need individual patients to go to the NICE website and provide feedback before the 7th of March. This is a life and death issue for our fellow MPN patients and the new US severe budget cutbacks assure a harder look at coverage for Jakafi in the States as well.
Speak out now..there’s not much time to register your opinion.
Comments on: "Will Jakafi be there when you need it?" (8)
What a great opportunity to actually influence a decision about insurance coverage for a drug that has great benefits for many in our select MPN group. Even if you don’t need it now, you may in the future. And if NICE gives a thumbs down to Jakafi on a cost- benefit basis, many other countries will follow suit. So let NICE hear our voices!
Zhen, I sent in all the pertinent positive info about my own experience with Jakavi and then sent a comment to MPNforum. I see the following notation under my comment “Your comment is awaiting moderation”. Could you tell me what this means. Is there something that I left out? Kindly advise. Yours truly, Barry Millman
Sorry, Barry, please don’t take offense. It probably means you’re not a subscriber to MPNforum. All comments by subscribers are posted automatically. Placing non-subscriber comments in a moderation queue isjust a way the system has to screen for spam. You can subscribe — free, of course — on most pages of any issue of MPNforum simply by supplying an e-mail address. Thanks, Zhen
Just completed my own positive comments.
Consider it done!
Should USA patients make a statement ?
Absolutely… The sooner, the stronger, the better!